STEMI急性期新发房颤的临床特征、抗栓策略与预后
该回顾性队列研究纳入142例接受急诊PCI且合并房颤的STEMI患者,其中新发房颤81例(57.0%),既往房颤61例。新发房颤组年龄较小,糖尿病、既往卒中比例及CHA2DS2-VASc、HAS-BLED评分均较低,Killip Ⅳ级比例较高。多因素Cox回归显示新发房颤与不良预后无独立相关性(HR=0.73,95%CI:0.31~1.69,P=0.459)。
要点
- STEMI急性期行急诊PCI合并房颤者中,超过半数为新发房颤(57.0%)
- 新发房颤组出院后更多采用双联抗血小板治疗,既往房颤组更多采用抗凝联合双联抗血小板治疗
- 新发房颤与STEMI患者12个月不良预后无独立相关性
核心结论
- 接受急诊PCI治疗的STEMI急性期房颤患者中超过半数为新发房颤,新发房颤组合并糖尿病、卒中比例较低,出院后长期抗栓更多采用双联抗血小板治疗,且新发房颤与不良预后无独立相关性。
研究设计与样本
- 回顾性队列研究,连续纳入2016年3月至2022年3月于解放军北部战区总医院经急诊绿色通道行冠状动脉造影及急诊PCI且合并房颤的142例STEMI患者。
- 研究对象分为既往房颤组(n=61)与新发房颤组(n=81)。
主要发现
- 142例STEMI患者年龄为(68.0±11.5)岁,男性104例(73.2%),新发房颤占比57.0%(81/142)。
- 与既往房颤组相比,新发房颤组年龄较小,合并糖尿病、既往卒中比例较低,CHA2DS2-VASc评分及HAS-BLED评分均较低,入院Killip Ⅳ级比例较高。
- 出院后长期抗栓中,新发房颤组更多采用双联抗血小板治疗[67例(82.7%)比37例(60.7%)],既往房颤组更多采用抗凝联合双联抗血小板治疗[20例(32.8%)比8例(9.9%),P<0.05]。
- 随访12个月,净不良临床事件发生率新发房颤组为18.5%(15/81),既往房颤组为24.6%(15/61),差异无统计学意义(P>0.05)。
- 多因素Cox回归分析显示新发房颤与STEMI患者不良预后无相关性(HR=0.73,95%CI:0.31~1.69,P=0.459)。
关键数值与推荐
- 新发房颤组出院后双联抗血小板治疗比例82.7%(67/81),既往房颤组为60.7%(37/61)。
- 既往房颤组出院后抗凝联合双联抗血小板治疗比例32.8%(20/61),新发房颤组为9.9%(8/81),P<0.05。
- 住院期间新发房颤组胺碘酮使用比例较高,ACEI或ARB使用率较低。
临床怎么用
- 对STEMI急性期新发房颤且接受急诊PCI者,若血栓及出血风险较低,可优先考虑双联抗血小板治疗作为出院后长期抗栓方案。
- 新发房颤并非不良预后的独立危险因素,临床评价时应关注患者整体风险而非仅凭新发房颤调整强度。
局限性
- 研究为单中心回顾性队列设计,样本量142例,新发房颤与既往房颤组间基线差异可能对结果产生影响。
- 随访时间为12个月,未报告更长周期预后及抗栓策略变化情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical characteristics and antithrombotic treatment strategies in patients with acute ST-segment elevation myocardial infarction (STEMI) who develop new-onset atrial fibrillation during the acute phase and undergo emergency percutaneous coronary intervention (PCI), and to evaluate the association between new-onset atrial fibrillation and prognosis in STEMI patients. Methods: This retrospective cohort study consecutively enrolled 142 STEMI patients with atrial fibrillation who underwent coronary angiography and emergency PCI via the emergency green channel at the Department of Cardiology, General Hospital of Northern Theater Command from March 2016 to March 2022. Patients were divided into two groups based on the presence of new-onset atrial fibrillation: the prior atrial fibrillation group (n=61) and the new-onset atrial fibrillation group (n=81). Clinical baseline data, in-hospital and long-term antithrombotic strategies after discharge, and adverse events during follow-up were recorded and compared between the two groups. Multivariate Cox regression analysis was used to assess the association between new-onset atrial fibrillation and adverse outcomes. Results: The mean age of the 142 STEMI patients was (68.0±11.5) years, with 104 males accounting for 73.2%. New-onset atrial fibrillation accounted for 57.0% (81/142) of the patients. Compared with the prior atrial fibrillation group, patients in the new-onset atrial fibrillation group were younger, had a lower prevalence of diabetes and previous stroke, and had lower CHA2DS2-VASc and HAS-BLED scores. Additionally, a higher proportion of patients in the new-onset atrial fibrillation group presented with Killip class Ⅳ at admission. During hospitalization, the new-onset atrial fibrillation group had a higher proportion of amiodarone use and lower prescription rates of angiotensin-converting enzyme inhibitors or angiotensin Ⅱ receptor blockers. Regarding long-term antithrombotic strategies after discharge, patients in the new-onset atrial fibrillation group more frequently received dual antiplatelet therapy (67 (82.7%) vs. 37 (60.7%)), while those in the prior atrial fibrillation group more often received anticoagulation combined with dual antiplatelet therapy (20 (32.8%) vs. 8 (9.9%), P<0.05). During 12-month follow-up, the incidence of net adverse clinical events was 18.5% (15/81) in the new-onset atrial fibrillation group and 24.6% (15/61) in the prior atrial fibrillation group, with no significant difference between the two groups (P>0.05). Multivariate Cox regression analysis confirmed that new-onset atrial fibrillation was not independently associated with adverse outcomes (HR=0.73, 95%CI: 0.31-1.69, P=0.459). Conclusions: More than half of the STEMI patients with atrial fibrillation undergoing emergency PCI had new-onset atrial fibrillation, characterized by a lower prevalence of diabetes and stroke, as well as a greater likelihood of receiving dual antiplatelet therapy as the long-term post-discharge antithrombotic strategy. However, new-onset atrial fibrillation was not independently associated with adverse outcomes. 目的: 探讨接受急诊冠状动脉介入治疗的急性ST段抬高型心肌梗死(STEMI)急性期新发心房颤动(房颤)患者的临床特征、抗栓治疗策略,以及新发房颤与STEMI患者预后的相关性。 方法: 本研究为回顾性队列研究,连续纳入2016年3月至2022年3月于解放军北部战区总医院心血管内科经急诊绿色通道行冠状动脉造影及急诊经皮冠状动脉介入治疗,同时合并心房颤动的142例STEMI患者为研究对象,根据是否为新发房颤,分为既往房颤组(n=61)与新发房颤组(n=81)。记录并比较两组患者的临床基线资料、院内和出院后长期抗栓策略以及随访期间不良事件发生情况,并通过多因素Cox回归分析新发房颤与不良预后的相关性。 结果: 142例STEMI患者年龄(68.0±11.5)岁,男性104例(73.2%),新发房颤57.0%(81/142)。与既往房颤组相比,新发房颤组年龄较小,合并糖尿病、既往卒中比例较低,同时CHA2DS2-VASc评分及HAS-BLED评分均较低,入院后Killip Ⅳ级比例较高;新发房颤组患者住院期间胺碘酮使用比例较高、血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂药物的使用率较低。对于出院后长期抗栓策略选择,新发房颤组更多采用双联抗血小板治疗[67(82.7%)比37(60.7%)],而既往房颤组更多选择抗凝联合双联抗血小板治疗[20例(32.8%)比8例(9.9%)],差异有统计学意义(P<0.05)。随访12个月,净不良临床事件发生率新发房颤组为18.5%(15/81),既往房颤组为24.6%(15/61),差异无统计学意义(P>0.05)。多因素Cox回归分析显示新发房颤与STEMI患者不良预后无相关性(HR=0.73,95%CI:0.31~1.69,P=0.459)。 结论: 接受急诊PCI治疗的STEMI急性期房颤患者中超过半数为新发房颤,其合并糖尿病、卒中的比例较低,出院后长期抗栓策略更多采用双联抗血小板治疗,新发房颤与不良预后无相关性。.
引用
- Zhai, Sun, Wang, et al. [Clinical characteristics, antithrombotic therapy, and prognosis of new-onset atrial fibrillation in the acute phase of ST-segment elevation myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 42324104. doi:10.3760/cma.j.cn112148-20250707-00494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。